Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 7/20 | 0.64 |
| ▸ | TNF | P01375 | 3/20 | 0.64 |
| ▸ | USP2 | O75604 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.64 |
| ▸ | ACHE | P22303 | 1/20 | 0.64 |
| ▸ | PDE4A | P27815 | 1/20 | 0.64 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.64 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.64 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.64 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.64 |
| ▸ | CHIT1 | Q13231 | 1/20 | 0.58 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.58 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6904012 | 1.00 | ADORA2B (0.64) | ADORA2BTNFUSP2LMNACYP1A2 | |
| SCHEMBL6902485 | 1.00 | ADORA2B (0.64) | ADORA2BTNFUSP2LMNACYP1A2 | |
| SCHEMBL1495174 | 0.93 | ADORA2B (0.56) | ADORA2BTNFUSP2LMNACYP1A2 | |
| SCHEMBL1495046 | 0.93 | ADORA2B (0.56) | ADORA2BTNFUSP2LMNACYP1A2 | |
| SCHEMBL1495161 | 0.93 | ADORA2B (0.56) | ADORA2BTNFUSP2LMNACYP1A2 | |
| SCHEMBL15790447 | 0.90 | ADORA2B (0.67) | ADORA2BTNFUSP2LMNACYP1A2 | |
| Bisdionin D SCHEMBL16120988 | 0.88 | ADORA2B (0.79) | ADORA2BTNFUSP2LMNACYP1A2 | |
| SCHEMBL12758277 | 0.88 | ADORA2B (0.61) | ADORA2BTNFUSP2LMNACYP1A2 | |
| SCHEMBL12758270 | 0.88 | ADORA2B (0.61) | ADORA2BTNFUSP2LMNACYP1A2 | |
| SCHEMBL12758271 | 0.88 | ADORA2B (0.61) | ADORA2BTNFUSP2LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5670506-A | ANTIINFLAMMATORY AGENTS, FUNGICIDES, MICROBIOCIDES | CELL THERAPEUTICS, INC. (US) | 1997-09-23 | — | — | US | claimed |
| US-10335413-B2 | Substituted xanthine derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-9918987-B2 | Substituted xanthine derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-9918987-B2 | Substituted xanthine derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2018-03-20 | — | — | US | disclosed |
| EP-3199203-A1 | SUBSTITUED XANTHINE DERIVATIVES | Concert Pharmaceuticals Inc. (US) | 2017-08-02 | — | — | EP | disclosed |
| US-20170027946-A1 | SUBSTITUTED XANTHINE DERIVATIVES | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2017-02-02 | — | — | US | disclosed |
| US-20170027946-A1 | SUBSTITUTED XANTHINE DERIVATIVES | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2017-02-02 | — | — | US | disclosed |
| US-9493463-B2 | Substituted xanthine derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-9492457-B2 | Substituted xanthine derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-9492457-B2 | Substituted xanthine derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-20110053961-A1 | SUBSTITUTED XANTHINE DERIVATIVES | CONCERT PHARMACEUTICALS, INC. | 2011-03-03 | — | — | US | disclosed |
| US-20110053961-A1 | SUBSTITUTED XANTHINE DERIVATIVES | CONCERT PHARMACEUTICALS, INC. | 2011-03-03 | — | — | US | disclosed |
| US-20090239886-A1 | Substituted xanthine derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2009-09-24 | — | — | US | disclosed |
| US-20090239886-A1 | Substituted xanthine derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2009-09-24 | — | — | US | disclosed |
| WO-2009108375-A1 | SUBSTITUTED XANTHINE DERIVATIVES | CONCERT PHARMACEUTICALS, INC (US) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009108383-A2 | SUBSTITUTED XANTHINE DERIVATIVES | CONCERT PHARMACEUTICALS, INC. (US) | 2009-09-03 | — | — | WO | disclosed |
| US-5670506-A | ANTIINFLAMMATORY AGENTS, FUNGICIDES, MICROBIOCIDES | CELL THERAPEUTICS, INC. (US) | 1997-09-23 | — | — | US | disclosed |
| EP-0714302-A4 | THERAPEUTIC COMPOUNDS | CELL THERAPEUTICS INC (US) | 1996-10-09 | — | — | EP | disclosed |
| EP-0714302-A1 | THERAPEUTIC COMPOUNDS | CELL THERAPEUTICS, INC. (US) | 1996-06-05 | — | — | EP | disclosed |
| WO-1994022449-A1 | THERAPEUTIC COMPOUNDS | CELL THERAPEUTICS, INC. (US) | 1994-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053961-A1 | SUBSTITUTED XANTHINE DERIVATIVES | XDH, HPRT1, CXCR3 | ADORA2B 60/4885TNF 583/4885USP2 4016/4885 |
| US-20170027946-A1 | SUBSTITUTED XANTHINE DERIVATIVES | XDH, HPRT1, CXCR3 | ADORA2B 60/4885TNF 583/4885USP2 4016/4885 |
| US-20090239886-A1 | Substituted xanthine derivatives | XDH, HPRT1, CXCR3 | ADORA2B 60/4885TNF 583/4885USP2 4016/4885 |
| US-10335413-B2 | Substituted xanthine derivatives | XDH, HPRT1, CXCR3 | ADORA2B 60/4885TNF 583/4885USP2 4016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.